Search results for B7

MAC, Human, mAb B7, Hycult Biotech, HM2443

The monoclonal B7 antibody (HM2443) recognizes a C9 epitope of the membrane attack complex (MAC). The three distinct activation pathways of complement converge with the formation of a C3 convertase and subsequently C3b. This initiates the formation of the C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the three activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 to C5b facilitates binding of C7, which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associates to the C5b-8 complex to form C5b-9, which is also termed as MAC. The formation of MAC causes lysis of cells when the incorporated C9 molecules of the complex unite into a pore-forming structure. The B7 antibody can be used to stain C5b-9 (or MAC) deposition in tissues and can recognize both C9 and soluble C5b-9 (sC5b-9/TCC) in fluid-phase matrices, like serum or plasma.

MPO, Human, mAb B7, Hycult Biotech, HM2288

The monoclonal antibody B7 recognizes human myeloperoxidase (MPO), an ~135 glycoprotein expressed in all cells of the myeloid linage. MPO functions as an α2β2 heteromultimer consisting of two heavy (α) and two light (β) chains of 55 and 15 kDa respectively. MPO is abundantly present in azurophilic granules of polymorphonuclear neutrophils (PMNs). It is an important enzyme used during phagocytic lysis of engulfed foreign particles which takes part in the defense of the organism through production of hypochlorous acid (HOCl), a potent oxidant. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity. Upon activation of neutrophils, MPO can be rapidly released and as such useful in body fluids as marker for inflammatory status. Involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer, Alzheimer’s disease, inflammatory bowel disease and multiple sclerosis. Autoimmune antibodies to MPO (so called ANCA) are involved in Wegener’s disease. Since the discovery of MPO deficiency, initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted more clinical attention.

MPO, Mouse, mAb B7, Hycult Biotech, HM1135

The monoclonal antibody B7 recognizes human myeloperoxidase (MPO), an ~135 glycoprotein expressed in all cells of the myeloid linage. MPO functions as an α2β2 heteromultimer consisting of two heavy (α) and two light (β) chains of 55 and 15 kDa respectively. MPO is abundantly present in azurophilic granules of polymorphonuclear neutrophils (PMNs). It is an important enzyme used during phagocytic lysis of engulfed foreign particles which takes part in the defense of the organism through production of hypochlorous acid (HOCl), a potent oxidant. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity. Upon activation of neutrophils, MPO can be rapidly released and as such useful in body fluids as marker for inflammatory status. Involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer, Alzheimer’s disease, inflammatory bowel disease and multiple sclerosis. Autoimmune antibodies to MPO (so called ANCA) are involved in Wegener’s disease. Since the discovery of MPO deficiency, initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted more clinical attention.

MPO, Rat, mAb B7, Hycult Biotech, HM3039

The monoclonal antibody B7 recognizes human myeloperoxidase (MPO), an ~135 glycoprotein expressed in all cells of the myeloid linage. MPO functions as an α2β2 heteromultimer consisting of two heavy (α) and two light (β) chains of 55 and 15 kDa respectively. MPO is abundantly present in azurophilic granules of polymorphonuclear neutrophils (PMNs). It is an important enzyme used during phagocytic lysis of engulfed foreign particles which takes part in the defense of the organism through production of hypochlorous acid (HOCl), a potent oxidant. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity. Upon activation of neutrophils, MPO can be rapidly released and as such useful in body fluids as marker for inflammatory status. Involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer, Alzheimer’s disease, inflammatory bowel disease and multiple sclerosis. Autoimmune antibodies to MPO (so called ANCA) are involved in Wegener’s disease. Since the discovery of MPO deficiency, initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted more clinical attention.

HLA-B7 Antibody (PE), Abbexa, abx140276

HLA-B7 Antibody is a Mouse Monoclonal against HLA-B7.

Serpin B7 (SERPINB7) Antibody, Abbexa, abx034017

SERPINB7 might function as an inhibitor of Lys-specific proteases and might influence the maturation of megakaryocytes via its action as a serpin.

Anti-B7-H6 antibody, Abcam, AB229999

HLA-B7 antibody [BB7.1], Genetex, GTX639674

Thrombospondin antibody [TSP-B7], Genetex, GTX11579

B7-H4 antibody, Internal, Genetex, GTX88996